TrumpRx: Will it impact Rx benefit plans?

By Martin Fornataro

The new prescription drug pricing website from the federal government, TrumpRx, launched in February 2026. Aimed primarily at the uninsured or underinsured, the goal of the site is to help Americans access many popular brand name drugs at a lower cost.

The website will not sell or dispense medications but instead acts as a coupon platform to assist people in finding discounted cash prices on select, high-cost drugs – bypassing traditional pharmacy benefit programs. TrumpRx includes more than 40 brand name medications used to treat medical conditions like infertility, diabetes, inflammation, respiratory issues, smoking cessation and GLP-1s. Around half of the drugs offering discounts via the TrumpRx site have generic equivalents.

The TrumpRx site is aimed at people who want to use a brand-name, or don’t have existing coverage for a medication. For example, if a person would like to use a GLP-1 for weight loss but they don’t meet their pharmacy plan’s coverage requirements or their plan doesn’t cover the medication for weight loss, they could find coupons or discounts on the new federal website that might help make these medications more affordable and accessible. These drugs would be paid for out-of-pocket directly by the person and not process through their  benefit plan.

Will this impact Employer-Sponsored Rx Plans?

The short answer is it doesn’t – mostly.

• Where plans won’t notice a change: TrumpRx is a cash-only discount card program that operates much like GoodRx. When plan participants pay for medications directly, those costs are not applied to deductibles or out-of-pocket maximums, and the drug costs do not roll back to the benefit plan.
• Where plans might see a change: The current administration seeks to reduce U.S. prescription drug costs by attaching them to the lowest prices paid by other developed nations, or what is known as Most Favored Nation (MFN) pricing. MFN favors low net cost over maximizing rebates, bypassing often unclear rebate sharing arrangements and situations where a plan has concerns about their Pharmacy Benefit Manager not sharing 100% of the manufacturer rebate. MFN and sites like TrumpRx may motivate drug manufacturers to lower their costs, which, in turn, could lower plan costs.

Regardless of how plans may or may not be impacted by sites like TrumpRx, plans should continue to encourage participants to check their plan’s drug pricing tool, before paying out of pocket, as generic or plan-covered options may be available at a lower cost.

Is your Plan looking to improve participant coverage, reduce high-dollar claims, or improve access to medications and care? Rael & Letson can help. Contact us to learn more.